Pharmacokinetic Study to Evaluate the Whole Blood Pharmacokinetics of TP-03 Following Six Week Topical Ocular Administration
Latest Information Update: 17 Apr 2024
Price :
$35 *
At a glance
- Drugs Lotilaner (Primary)
- Indications Blepharitis; Eye disorders; Lyme disease
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Tarsus Pharmaceuticals
- 10 Apr 2024 Status changed from active, no longer recruiting to completed.
- 03 Dec 2021 New trial record